Drug Profile
Research programme: hepatitis C therapeutics - REPLICor
Alternative Names: Amphipathic DNA polymers - REPLICor; Hepatitis C programme - REPLICor; Phosphorothioate oligonucleotides - REPLICor; PS-ONs - REPLICor; REP 9CLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator REPLICor
- Class
- Mechanism of Action Viral fusion protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)